Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Effect of valsartan and carvedilol on TNFα, IL-6 and angiotensin α on geriatric chronic heart failure
View through CrossRef
Objective
To observe the effect of Valsartan and carvedilol on TNFα, IL-6 and angiotensin II (Ang II) in geriatric chronic heart failure (CHF).
Methods
95 cases of the aged patients with CHF were randomised into two groups, valsartan group and valsartan combined carvedilol group. Radioactive immunoassays were used to measure the levels of Ang II, TNFα and IL-6 before treatment and three months after treatment.
Results
Blood plasma TNFα and IL-6 levels fell down in valsartan group and valsartan combined carvedilol group after treatment (p<0.01). There was no significant difference of Ang II after treatment between the two groups (p>0.05).
Conclusions
Cardiac function of CHF was improved significantly after treatment of valsartan or valsartan combined carvedilol. Treatment of valsartan combined carvedilol is better than that of valsartan in decrease of blood plasma TNFα and IL-6 levels and improvement of cardiac function.
Title: Effect of valsartan and carvedilol on TNFα, IL-6 and angiotensin α on geriatric chronic heart failure
Description:
Objective
To observe the effect of Valsartan and carvedilol on TNFα, IL-6 and angiotensin II (Ang II) in geriatric chronic heart failure (CHF).
Methods
95 cases of the aged patients with CHF were randomised into two groups, valsartan group and valsartan combined carvedilol group.
Radioactive immunoassays were used to measure the levels of Ang II, TNFα and IL-6 before treatment and three months after treatment.
Results
Blood plasma TNFα and IL-6 levels fell down in valsartan group and valsartan combined carvedilol group after treatment (p<0.
01).
There was no significant difference of Ang II after treatment between the two groups (p>0.
05).
Conclusions
Cardiac function of CHF was improved significantly after treatment of valsartan or valsartan combined carvedilol.
Treatment of valsartan combined carvedilol is better than that of valsartan in decrease of blood plasma TNFα and IL-6 levels and improvement of cardiac function.
Related Results
Carvedilol ameliorates experimental atherosclerosis by inhibiting the NLRP3 inflammasome
Carvedilol ameliorates experimental atherosclerosis by inhibiting the NLRP3 inflammasome
Abstract
Objective: To investigate the protective effect of carvedilol against atherosclerosis by inhibiting the NLRP3 inflammasome.
Methods：In vitro experiments, human umb...
Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
The development and progression of heart failure (HF) due to myocardial infarction (MI) is a major concern even with current optimal therapy. Resveratrol is a plant polyphenol with...
Kajian Literatur Profil Farmakokinetika Sacubitril-Valsartan Pada Subjek Sehat dan Gagal Jantung
Kajian Literatur Profil Farmakokinetika Sacubitril-Valsartan Pada Subjek Sehat dan Gagal Jantung
Abstract. Sacubitril-Valsartan is a first-class therapeutic agent for ARNI (Angiotensin Receptor-Neprilysin Inhibitor) which can reduce blood pressure and reduce mortality and morb...
Effect of Lercanidipine on the Pharmacokinetics‐Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease
Effect of Lercanidipine on the Pharmacokinetics‐Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease
AbstractThis study evaluates the carvedilol‐lercanidipine drug interaction, and the influence of chronic kidney disease (CKD) on both drugs. Patients with high blood pressure (8 wi...
Development of angiotensin (1‐7) as an agent to accelerate dermal repair
Development of angiotensin (1‐7) as an agent to accelerate dermal repair
Angiotensin II has been shown to be a potent agent in the acceleration of wound repair. Angiotensin (1‐7), a fragment of angiotensin II that is not hypertensive, was found to be co...
Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study
Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study
Abstract:
Nitrosamine contamination of generic valsartan was found in 2018. This study aimed to investigate whether long-term use of valsartan increases cancer risk. Pati...
Abstract 125: Modified Angiotensin II Has Lower Vasoconstrictive Effect Than Angiotensin II
Abstract 125: Modified Angiotensin II Has Lower Vasoconstrictive Effect Than Angiotensin II
Introduction:
The renin-angiotensin-aldosterone system (RAAS) is involved in the regulation of the blood pressure, water- and electrolyte balance. Pathophysiologically,...
TNFα‐induced activation of eosinophil oxidative metabolism and morphology ‐ Comparison with IL‐5*
TNFα‐induced activation of eosinophil oxidative metabolism and morphology ‐ Comparison with IL‐5*
Abstract Human dermal mast cells are capable of releasing cytokines, particularly preformed TNFα, upon appropriate stimulation. Masl cell activation in vivo was shown to be associa...